Os Ingrid, Stenehjem Aud, Høieggen Aud, Draganov Branimir, Jenssen Trond, Holdaas Hallvard
Nyremedisinsk avdeling Ullevål universitetssykehus 0407 Oslo.
Tidsskr Nor Laegeforen. 2002 Apr 10;122(9):918-20.
In industrialised countries the incidence of type 2 diabetes-associated end stage renal disease has doubled over the last ten years. It is important to lower the blood pressure to inhibit progression of renal failure and to prevent micro- and macrovascular disease in these patients. There is an ongoing discussion on what should be the drug of choice.
We discuss the results from three landmark studies, recently published, on the use of angiotensin II antagonists in patients with type 2 diabetics and nephropathy.
All three studies found a renoprotective effect of angiotensin II antagonists that could not be explained by the effect on the blood pressure alone. Blockade of the renin angiotensin system with angiotensin II antagonist should be the basis of treatment in type 2 diabetic nephropathy.
在工业化国家,2型糖尿病相关终末期肾病的发病率在过去十年中翻了一番。降低血压对于抑制肾衰竭进展以及预防这些患者的微血管和大血管疾病很重要。关于哪种药物应作为首选药物存在持续的讨论。
我们讨论了最近发表的三项关于血管紧张素II拮抗剂在2型糖尿病和肾病患者中应用的具有里程碑意义的研究结果。
所有三项研究均发现血管紧张素II拮抗剂具有肾脏保护作用,这不能仅通过其对血压的影响来解释。使用血管紧张素II拮抗剂阻断肾素血管紧张素系统应作为2型糖尿病肾病治疗的基础。